PepWay
“Compounded,” “same molecule” and “equivalent” often appear together in advertising, but they describe different questions. Discussing a product requires its identity and regulatory context. A phone record cannot verify composition, sterility or approval.
Compounding does not constitute medicine approval
FDA explains that compounded products do not undergo the same premarket review as an approved medicine. This describes the United States system rather than a rule to transfer automatically to another country. In Brazil, Anvisa announced measures addressing GLP-1 importation and compounding irregularities in April 2026. Local, current information matters. A facility authorization, a company document and a medicine’s registration answer different questions. Ask which document supports a particular claim before interpreting a business credential as evidence about a specific medicinal product.
The ingredient name leaves essential questions open
Semaglutide or tirzepatide on a label alone does not establish equivalence to an approved product. Composition, chemical form, concentration, packaging and quality controls matter. FDA has specific concerns about semaglutide salt forms and errors involving compounded preparations. Do not try to resolve those differences through a home calculation. If information is incomplete or inconsistent, preserve the original document and request professional assessment. An app cannot identify a substance or confirm what a container contains. The appearance of a product is also insufficient to settle its identity or suitability.
Documents can support discussion without certifying a product
Keep the complete name, stated manufacturer or responsible entity, lot, expiry, receipt date and written guidance. If packaging is damaged, documents conflict or storage is uncertain, record the fact and seek professional clarification before making a use decision. A certificate attached to advertising should correspond to the discussed product and batch; even then, it cannot replace regulatory evaluation. An organized spreadsheet does not compensate for missing documentation or establish that a container was stored appropriately. Treat records as information for assessment, rather than as an independent assurance of quality.
An example checklist for an equivalence claim
When an advertisement says “same as the original,” write four questions: which approved product is the comparator; which formulation; in which country; what data establish equivalence? Add the link, date and a readable label photograph when available, protecting personal information. An example note might say: “advertisement names semaglutide but does not identify its chemical form or comparison product.” This is an information problem to discuss, rather than a reason to infer an answer from price or appearance. Keep any unanswered question visible until clarification arrives.
Regulatory changes require specific review
Product availability, new rules and oversight updates may change the compounding context. Do not treat an old article as permanent authorization. Ask your team how current requirements apply to the particular product and your clinical need. For a suspected adverse event or quality problem, obtain care and guidance about reporting through the appropriate official channel. Advertising, personal records and other users’ experiences serve different purposes from safety evaluation and professional medicine verification. A useful record preserves the exact claim and date so that later discussion can address what was actually presented.
Frequently asked questions
Does a certificate of analysis establish clinical safety?
No. It may describe tests on a sample. Clinical safety, personal suitability and regulatory status are separate questions.
Do United States rules automatically apply in Brazil?
No. Consult current Brazilian information and your responsible healthcare team; the authorities and processes are different.
Sources and references
Documents and research consulted for this article. Each source describes its own context; a reference does not confirm every use of a substance.
- FDA concerns with unapproved GLP-1 drugs (opens in a new tab)FDA · Accessed October 14, 2026
- Medidas contra irregularidades na importação e manipulação de GLP-1 (opens in a new tab)Anvisa · Accessed October 14, 2026
- Understanding the risks of compounded drugs (opens in a new tab)FDA · Accessed October 14, 2026
